Amneal Pharmaceuticals (AMRX) Total Debt (2017 - 2026)

Amneal Pharmaceuticals' Total Debt history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• On a quarterly basis, Total Debt rose 17.94% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $2.6 billion, a 17.94% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, down 1.21% from the prior year.
• Total Debt held at $2.6 billion in Q1 2026 per AMRX's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Total Debt topped out at $2.7 billion in Q1 2022 and bottomed at $69.2 million in Q3 2022.
• The 5-year median for Total Debt is $2.6 billion (2023), against an average of $2.3 billion.
• Across the five-year window, Total Debt jumped 3934.24% in 2022 and retreated 10.6% in 2025, its largest moves.
• Year by year, Total Debt stood at $2.6 billion in 2022, then fell by 0.87% to $2.6 billion in 2023, then rose by 0.43% to $2.6 billion in 2024, then slipped by 1.21% to $2.6 billion in 2025, then slipped by 0.03% to $2.6 billion in 2026.
• Per Business Quant, the three latest AMRX Total Debt figures stand at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.6 billion (Q3 2025).